A clinical study of relevance to KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

A clinical study of relevance to KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer - A relevance to KRAS mutations and acquired resistance to anti-EGFR therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013154

Enrollment

Registered

2014-04-01

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Kras wild type advance or recurrent colorectal cancer and will be treated with an anti-EGFR antibody

Exclusion criteria

Exclusion criteria: He or she had used anti-EGFR antibody previously, or prohibit on using anti-EGFR antibody

Design outcomes

Primary

Measure	Time frame
Detection of kras mutation in serum circulation DNA	—

Secondary

Measure	Time frame
Detection of other mutations related colorectal cancer in serum circulation DNA	—

Countries

Japan

Contacts

Public ContactYasuo Saijo

Niigata University Graduate School of Medical and Dental Sciences Department of Medical Oncology

yasosj@med.niigata-u.ac.jp025-368-9003

Outcome results